Marked insulin resistance in pregnancy

Practical Diabetes International

Volumn 23, Issue 3, 2006, Pages 115-117

  Evans, Kate M ^a   Millward, B Ann ^b,c  

^a TORBAY HOSPITAL   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

^c DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

Gestational diabetes; Insulin resistance

Indexed keywords

ANDROGEN; FOLLITROPIN; HEMOGLOBIN A1C; INSULIN; LUTEINIZING HORMONE; METFORMIN; NEUTRAL INSULIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONCEPTION; DELIVERY; DOSE RESPONSE; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; FEMALE INFERTILITY; GESTATIONAL AGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LABOR INDUCTION; MATERNAL DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; WEIGHT REDUCTION;

EID: 33751058179     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.917     Document Type: Article

References (24)

1. Nelson-Piercy C. Handbook of Obstetric Medicine. Oxford: Isis Medical Media, 1997;66-79.
2. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2005; 28(Suppl 1): S37-S42.
3. Radon PA, McMahon MJ, Meyer WR. Impaired glucose tolerance in pregnant women with polycystic ovarian syndrome. Obstet Gynae 1999; 94: 194-197.
4. Mikola M, Hiilesmaa V, Halttunen M, et al. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001; 16: 226-229.
5. Franks S. Polycystic ovarian syndrome. N Engl J Med 1995; 333: 853-861.
6. Dunaif A, Thomas A. Current concepts in the polycystic ovarian syndrome. Annu Rev Med 2001; 52: 410-419.
7. Ehrmann DA, Barnes RD, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovarian syndrome. Diabetes Care 1999; 22: 141-146.
8. Urman B, Sarac E, Dogan L, et al. Pregnancy in infertile PCOD patients: complications and outcomes. J Reprod Med 1997; 42: 501-505.
9. Holte J, Gennarelli G, Wide L, et al. High prevalence of polycystic ovaries and associated clinical, endocrine and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998; 83:1143-1150.
10. Paradisi G, Fulghesu AM, Ferrazani S, et al. Endocrino-metabolic features in women with polycystic ovarian syndrome during pregnancy. Hum Reprod 1998; 13: 542-546.
11. Gluek CJ, Wang P, Fontaine RN, et al. Plasminogen Activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovarian syndrome. Metabolism 1999; 48:1589-1595.
12. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovarian syndrome. J Clin Endocrinol Metab 2002; 87: 524-529.
13. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001; 16: 2606-2608.
14. Harborne L, Fleming R, Lyall H, et al. Descriptive review of the evidence for the use of metformin in polycystic ovarian syndrome. Lancet 2003; 361: 1894-1901.
15. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovarian syndrome: systematic review and metaanalysis. BMJ 2003; 327: 951-955.
16. Nestler JE, Jakubowicz DJ, Evans WS, et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovarian syndrome. N Eng J Med 1998; 338: 1876-1880.
17. Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomised double blind placebo controlled trial. J Clin Endocrinol Metab 2002; 87: 569-574.
18. Lord J, Flight I, Norman I. Insulin-sensitising drugs for PCOS. Cochrane Database Syst Rev 2003; 3: CDO03053.
19. Muth S, Norman J, Sattar N, et al. Women with polycystic ovary syndrome often undergo protracted treatment with metformin and are disinclined to stop: indications for a change in licensing arrangements? Hum Reprod 2004; 19: 2718-2720.
20. Gluek CJ, Wang P, Goldenberg N, et al. Pregnancy outcomes among women with polycystic ovary syndrome treated with mefformin. Hum Reprod 2002; 17: 2858-2864.
21. Gluek CJ, Wang P, Kobayashi S, et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes mellitus in women with polycystic ovarian syndrome. Fertil Steril 2002; 111: 665-666.
22. O'Rahilly S. Insights into obesity and insulin resistance from the study of extreme human phenotypes. Eur J Endocrinology 2002; 147: 435-441.
23. George S, Rochford JJ, Wolfrum C, et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 2004; 304: 1325-1328.
24. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005; 28:1240-1244.